JLE

Epileptic Disorders

MENU

Topiramate and temporal lobe epilepsy: an open-label study Volume 14, issue 2, June 2012

Aguglia U, Gambardella A, Le Piane E, et al. Mild non-lesional temporal lobe epilepsy. a common unrecognized disorder with onset in adulthood. Can J Neurol Sci 1998 ; 25 : 282-286.

Andreou AP, Goadsby P.J. Topiramate in the treatment of migraine: a kainite glutamate receptor antagonist within the trigeminothalamic pathway. Cephalgia 2011 ; 31 : 1343-1358.

Artinian J, Peret A, Marti G, Epsztein J, Crépel V. Synaptic kainite receptors in interplay with INA shift the sparse firing of dentate granule cells to a sustained rhythmic mode in temporal lobe epilepsy. J Neurosci 2011 ; 31 : 10811-10818.

Bergey G.K. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 2005 ; 46 : 161-168.

Commission on Classification Terminology of the International League Against Epilepsy Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989 ; 30 : 389-399.

El Yaman SH, Mroueh SM, Sinno DD, Mikati M.A. Long-term patterns of weight changes during topiramate therapy: an observational study. Neurology 2007 ; 69 : 310-311.

Gambardella A, Pucci F, La Piane E, et al. Usefulness of latero-orbital electrodes in detecting interictal epileptiform activity-a study of 60 patients with complex partial seizures. Electroencephalogr Clin Neurophysiol 1998 ; 107 : 174-176.

Gambardella A, Manna I, Labate A, et al. GABA(B) receptor 1 polymorphism (G1465A) is associated with temporal lobe epilepsy. Neurology 2003 ; 60 : 560-563.

Giannakodimos ST, Georgiadis G, Tsounis ST, et al. Add-on topiramate in the treatment of refractory partial-onset epilepsy: clinical experience of outpatient epilepsy clinics from 11 general hospitals. Seizure 2005 ; 14 : 396-402.

Glauser TA, Levisohn PM, Ritter F, Sachdeo R.C. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000 ; 41 : S86-S90.

Herrero AI, Del Olmo N, González-Escalada JR, Solís J.M. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 2002 ; 42 : 210-220.

Jette N, Hemming K, Hutton JL, Marson A.G. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008 ; 3 : CD001417.

Kaminski RM, Banerjee M, Rogawski M.A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004 ; 46 : 1097-1104.

Labate A, Ventura P, Gambardella A, et al. MRI evidence of mesial temporal sclerosis in sporadic “benign” temporal lobe epilepsy. Neurology 2006 ; 66 : 562-565.

Labate A, Cerasa A, Gambardella A, Aguglia U, Quattrone A. Hippocampal and thalamic atrophy in mild temporal lobe epilepsy: a VBM study. Neurology 2008 ; 71 : 1094-1101.

Labate A, Gambardella A, Andermann E, et al. Benign mesial temporal lobe epilepsy. Nat Rev Neurol 2011 ; 7 : 237-240.

Park HJ, Kim HJ, Park HJ, et al. Protective effect of topiramate on kainic acid-induced cell death in mice hippocampus. Epilepsia 2008 ; 49 : 163-167.

Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 1997 ; 38 : 294-300.

Siniscalchi A, Gallelli L, De Sarro G.B. Use of antiepileptic drugs for hyperkinetic movement disorders. Curr Neuropharmacol 2010 ; 8 : 359-366.